Antivirals TRIZ Cases
- Combination Therapy for EV71 Infection Using Synergistic Drug Mixture
A combination therapy using auranofin, ouabain, emetine, niclosamide, and fluoxetine suppresses EV71 replication through synergistic activity.
- Small-Molecule Entry Inhibitors Block SARS-CoV-2 Spike Binding
Small-molecule entry inhibitors bind to the SARS-CoV-2 spike receptor binding domain interface to block viral attachment.
- Ozonide Derivatives for HCMV Replication Suppression
OZ418 ozonides suppress cytomegalovirus replication while reducing bone marrow and kidney toxicity associated with standard antiviral therapies.
- HBV Antiviral Compounds Disrupting Capsid Assembly
Formula I compounds disrupt HBV capsid assembly to reduce viral load, overcoming drug resistance and tolerability issues in chronic infection treatment.
- CDK7 Inhibitors Targeting Host Machinery for Resistant DNA Viruses
Covalent CDK7 inhibitors block host cell machinery to treat resistant herpesvirus and papillomavirus infections without triggering rapid drug resistance.
- Cyclosporine Analogues Inhibit HCV Replication via Cyclophilin A Binding
Modified cyclosporine analogues bind host cyclophilin A to inhibit viral replication while reducing immunosuppressive side effects.
- Young Barley Grass Composition for Regulatory T Cell Modulation
Young barley grass composition increases regulatory T cells while suppressing excessive immune responses to prevent autoimmune diseases.
- Hepatitis B Capsid Assembly Modulators for Viral Suppression
Small molecule compounds modulate hepatitis B core protein assembly to inhibit viral replication and reduce HBV DNA levels.